Aardvark Therapeutics, Inc.

Soleno Therapeutics has gained US approval for Vykat XR, making it the first ever drug to treat hyperphagia, an intense, persistent hunger experienced by people with the rare genetic disorder Prader-W

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

A thriving market for initial public offerings is essential for biopharmaceutical industry growth as firms seek to expand drug development programs beyond the scope of what their venture capital backe

Aardvark Therapeutics’ drug candidates are designed to reduce hunger, but the company worked up enough of an appetite among investors to support the company’s initial public offering – the fifth bioph